Lanean...

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?

BACKGROUND: Population‐based studies previously showed an improvement in overall survival (OS) for patients with diffuse large B‐cell lymphoma (DLBCL) who received chemoimmunotherapy with rituximab. However, there is limited data (especially at the population level) that show a similar trend in OS i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: Epperla, Narendranath, Vaughn, John L., Othus, Megan, Hallack, Abrahao, Costa, Luciano J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7402846/
https://ncbi.nlm.nih.gov/pubmed/32558356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3237
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!